Research Progress on the Impact of SGLT-2 on Epicardial Fat
Research Article
Open Access
CC BY

Research Progress on the Impact of SGLT-2 on Epicardial Fat

Xuecong Sun 1*
1 Capital Medical University 6th clinical medical school
*Corresponding author: AtuanXiaomi@outlook.com
Published on 24 September 2025
Journal Cover
TNS Vol.137
ISSN (Print): 2753-8826
ISSN (Online): 2753-8818
ISBN (Print): 978-1-80590-371-0
ISBN (Online): 978-1-80590-372-7
Download Cover

Abstract

Epicardial adipose tissue (EAT) refers to a special type of coronary fat that is in direct contact with the myocardium and coronary arteries with no other tissue separating it.The results of many recent studies have shown that abnormal changes in the adipose tissue of the outer mucosa of the Heart play an important role in the development of various cardiovascular diseases, such as atrial fibrillation, coronary atherosclerosis, and electrical remodeling of the heart, as well as being closely associated with an increased risk of complications after surgery. However, SGLT - 2 inhibitors, a novel class of therapeutic agents, have demonstrated remarkable efficacy in ameliorating the pathological state of epicardial adipose tissue. This finding furnishes a novel mechanistic basis for the prophylaxis of cardiovascular diseases. This article will examine in detail the potential mechanism of action of the SGLT-2 inhibitor in improving the condition in the adipose tissue of the outer mucosa of the heart aiming to achieve the preventive effect against cardiovascular diseases.It seeks to provide new perspectives and evidence for the prevention and fight against cardiovascular diseases.

Keywords:

Epicardial adipose tissue (EAT), SGLT-2, cardiovascular diseases

View PDF
Sun,X. (2025). Research Progress on the Impact of SGLT-2 on Epicardial Fat. Theoretical and Natural Science,137,40-45.

References

[1]. Yang ZA, Feng W. "Research Progress on Epicardial Adipose Tissue and New-Onset Atrial Fibrillation After Cardiac Surgery." Chinese Journal of Cardiovascular Disease Research 21.12(2023): 1138-1144

[2]. Wu, T., & Guo, X. (2022). Research progress on the protective effects of SGLT2 inhibitors on cardiovascular diseases. *Chinese Journal of Clinical Research*, *35*(2), 276-278, 283.https: //doi.org/10.13429/j.cnki.cjcr.2022.02.030

[3]. Conte M, Petraglia L, Cabaro S, et al. Epicardial adipose tissue and cardiac arrhythmias: Focus on atrial fibrillation［J］. Front Cardiovasc Med, 2022, 9: 932262. DOI: 10.3389 / fcvm. 2022. 932262

[4]. Masson W, Lavalle-Cobo A, Nogueira JP. Effect of SGLT2-Inhibitors on Epicardial Adipose Tissue: A Meta-Analysis. Cells. 2021; 10(8): 2150.https: //doi.org/10.3390/cells10082150

[5]. Bao Y, Hu Y, Shi M, Zhao Z. SGLT2 inhibitors reduce epicardial adipose tissue more than GLP-1 agonists or exercise interventions in patients with type 2 diabetes mellitus and/or obesity: A systematic review and network meta-analysis. Diabetes Obes Metab. 2025 Mar; 27(3): 1096-1112. doi: 10.1111/dom.16107. Epub 2024 Dec 6. PMID: 39639835.

[6]. Sato T, Aizawa Y, Yuasa S, Kishi S, Fuse K, Fujita S, Ikeda Y, Kitazawa H, Takahashi M, Sato M, Okabe M. The effect of dapagliflozin treatment on epicardial adipose tissue volume. Cardiovasc Diabetol. 2018 Jan 4; 17(1): 6. doi: 10.1186/s12933-017-0658-8. PMID: 29301516; PMCID: PMC5753537.

[7]. Iacobellis G. Local and systemic effects of the multifaceted epicardial adipose tissue depot. Nat Rev Endocrinol. 2015 Jun; 11(6): 363-71. doi: 10.1038/nrendo.2015.58. Epub 2015 Apr 7. PMID: 25850659.

[8]. Rick B. Vega, Understanding the Benefits of SGLT2  Inhibition∗: Direct Effect on Epicardial Adipose Tissue, JACC: Basic to Translational Science, Volume 8, Issue 9, 2023, Pages 1098-1099, ISSN 2452-302X, https: //doi.org/10.1016/j.jacbts.2023.07.001.

[9]. Li L, Hua C, Liu X, Wang Y, Zhao L, Zhang Y, Wang L, Su P, Yang MF, Xie B. SGLT2i alleviates epicardial adipose tissue inflammation by modulating ketone body-glyceraldehyde-3-phosphate dehydrogenase malonylation pathway. J Cardiovasc Med (Hagerstown). 2023 Apr 1; 24(4): 232-243. doi: 10.2459/JCM.0000000000001453. Epub 2023 Mar 2. PMID: 36938811.

[10]. Kasperova, B.J., Mraz, M., Svoboda, P. et al. Sodium-glucose cotransporter 2 inhibitors induce anti-inflammatory and anti-ferroptotic shift in epicardial adipose tissue of subjects with severe heart failure. Cardiovasc Diabetol 23, 223 (2024). https: //doi.org/10.1186/s12933-024-02298-9

References

[1]. Yang ZA, Feng W. "Research Progress on Epicardial Adipose Tissue and New-Onset Atrial Fibrillation After Cardiac Surgery." Chinese Journal of Cardiovascular Disease Research 21.12(2023): 1138-1144

[2]. Wu, T., & Guo, X. (2022). Research progress on the protective effects of SGLT2 inhibitors on cardiovascular diseases. *Chinese Journal of Clinical Research*, *35*(2), 276-278, 283.https: //doi.org/10.13429/j.cnki.cjcr.2022.02.030

[3]. Conte M, Petraglia L, Cabaro S, et al. Epicardial adipose tissue and cardiac arrhythmias: Focus on atrial fibrillation［J］. Front Cardiovasc Med, 2022, 9: 932262. DOI: 10.3389 / fcvm. 2022. 932262

[4]. Masson W, Lavalle-Cobo A, Nogueira JP. Effect of SGLT2-Inhibitors on Epicardial Adipose Tissue: A Meta-Analysis. Cells. 2021; 10(8): 2150.https: //doi.org/10.3390/cells10082150

[5]. Bao Y, Hu Y, Shi M, Zhao Z. SGLT2 inhibitors reduce epicardial adipose tissue more than GLP-1 agonists or exercise interventions in patients with type 2 diabetes mellitus and/or obesity: A systematic review and network meta-analysis. Diabetes Obes Metab. 2025 Mar; 27(3): 1096-1112. doi: 10.1111/dom.16107. Epub 2024 Dec 6. PMID: 39639835.

[6]. Sato T, Aizawa Y, Yuasa S, Kishi S, Fuse K, Fujita S, Ikeda Y, Kitazawa H, Takahashi M, Sato M, Okabe M. The effect of dapagliflozin treatment on epicardial adipose tissue volume. Cardiovasc Diabetol. 2018 Jan 4; 17(1): 6. doi: 10.1186/s12933-017-0658-8. PMID: 29301516; PMCID: PMC5753537.

[7]. Iacobellis G. Local and systemic effects of the multifaceted epicardial adipose tissue depot. Nat Rev Endocrinol. 2015 Jun; 11(6): 363-71. doi: 10.1038/nrendo.2015.58. Epub 2015 Apr 7. PMID: 25850659.

[8]. Rick B. Vega, Understanding the Benefits of SGLT2  Inhibition∗: Direct Effect on Epicardial Adipose Tissue, JACC: Basic to Translational Science, Volume 8, Issue 9, 2023, Pages 1098-1099, ISSN 2452-302X, https: //doi.org/10.1016/j.jacbts.2023.07.001.

[9]. Li L, Hua C, Liu X, Wang Y, Zhao L, Zhang Y, Wang L, Su P, Yang MF, Xie B. SGLT2i alleviates epicardial adipose tissue inflammation by modulating ketone body-glyceraldehyde-3-phosphate dehydrogenase malonylation pathway. J Cardiovasc Med (Hagerstown). 2023 Apr 1; 24(4): 232-243. doi: 10.2459/JCM.0000000000001453. Epub 2023 Mar 2. PMID: 36938811.

[10]. Kasperova, B.J., Mraz, M., Svoboda, P. et al. Sodium-glucose cotransporter 2 inhibitors induce anti-inflammatory and anti-ferroptotic shift in epicardial adipose tissue of subjects with severe heart failure. Cardiovasc Diabetol 23, 223 (2024). https: //doi.org/10.1186/s12933-024-02298-9

Cite this article

Sun,X. (2025). Research Progress on the Impact of SGLT-2 on Epicardial Fat. Theoretical and Natural Science,137,40-45.

Data availability

The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.

About volume

Volume title: Proceedings of ICBioMed 2025 Symposium: AI for Healthcare: Advanced Medical Data Analytics and Smart Rehabilitation

ISBN: 978-1-80590-371-0(Print) / 978-1-80590-372-7(Online)
Editor: Alan Wang
Conference website: https://2025.icbiomed.org/auckland.html
Conference date: 17 October 2025
Series: Theoretical and Natural Science
Volume number: Vol.137
ISSN: 2753-8818(Print) / 2753-8826(Online)

© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license. Authors who publish this series agree to the following terms:

1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.

2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.

3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open access policy for details).

For authors
For editors
For reviewers

Cookies are used by this site.
Copyright © 2024 EWA Publishing, its licensors, and contributors. All rights reserved, including text and data mining, AI training, and similar technologies.